我要投票 马应龙八宝Mabo's在眼霜行业中的票数:1025
· 外 推 电 报 ·
2026-05-14 00:53:55 星期四

【马应龙八宝Mabo's是哪个国家的品牌?】

马应龙八宝Mabo's是什么牌子?「马应龙八宝Mabo's」是 马应龙药业集团股份有限公司 旗下著名品牌。该品牌发源于湖北武汉,由创始人陈平经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力马应龙八宝Mabo's品牌出海!将品牌入驻外推网,定制马应龙八宝Mabo's品牌推广信息,可以显著提高马应龙八宝Mabo's产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

马应龙是一家经国家商务部认定的中华老字号企业,创始于公元1582年。经过多年持续快速健康发展,马应龙已经成为一家涉足于药品制造、药品研发、药品批发零售、连锁医院等多个领域的专业化多功能国际化的医药类上市公司。

公司与北京大学药学院、中国药科大学等多家科研机构建立了长期的战略合作关系。经国家人事部核准公司与北京大学共同组建了博士后工作站。2009年,马应龙药业集团股份有限公司技术中心被国家发改委、科技部等五部委认定为国家级企业技术中心,马应龙创新药物研发团队被湖北省委组织部认定为首批“湖北省重点产业创新团队”。

马应龙及旗下子公司分别通过了国家药监局GMP、GSP质量管理规范体系认证,获得国际权威机构SGS颁发的环境管理体系ISO14000和职业安全与健康管理体系OHSAS18000的认证,在医药行业内率先实现了“三认证”。在世界品牌实验室、世界经理人周刊联合评估的2009年“中国最具价值品牌500强”排行榜中,马应龙名列第213位,品牌价值达到了40.01亿元。2006年马应龙荣获国家工商总局认定的“驰名保护”。2009年,马应龙被中国非处方药物协会评选为“中国非处方药品牌企业十五强”

公司股票于2004年在上海证券交易所上市,由此获得了持续融资的通道和规范营运的平台。2007年,公司股票被上海证券交易所、中国证券指数公司选定为中国上市公司治理指数样本股,标志着公司治理水平获得社会公众、证券机构及专家的高度认可。

传承四百多年的历史文化,公司逐步形成了具有马应龙特色的企业文化体系。公司秉承“为顾客创造健康,为股东创造财富,为员工创造机会,为社会创造效益”的经营宗旨,倡导“以真修心,以勤修为”的哲学观,倡导“稳健经营、协调发展”的经营观,倡导“资源增值”的价值观,弘扬“龙马精神”的企业精神。马应龙将以实现中药现代化为己任,在品牌经营战略的指引下与时俱进,继往开来。


英文翻译:Ma Yinglong is a Chinese time-honored enterprise recognized by the Ministry of Commerce. It was founded in 1582 ad. After years of sustained, rapid and healthy development, Ma Yinglong has become a professional, multi-functional and international pharmaceutical listed company involved in drug manufacturing, drug research and development, drug wholesale and retail, chain hospitals and other fields. The company has established a long-term strategic cooperation relationship with many scientific research institutions, such as the school of pharmacy of Peking University and China Pharmaceutical University. With the approval of the Ministry of personnel of the people's Republic of China, the company and Peking University jointly set up a postdoctoral workstation. In 2009, the technology center of Ma Yinglong Pharmaceutical Group Co., Ltd. was recognized as a national enterprise technology center by five ministries and commissions including the national development and Reform Commission and the Ministry of science and technology, and the R & D team of Ma Yinglong innovative drugs was recognized as the first batch of "Hubei key industry innovation team" by the Organization Department of Hubei Provincial Committee. Ma Yinglong and its subsidiaries have respectively passed the GMP and GSP quality management standard system certification issued by the State Food and drug administration, obtained the certification of ISO14000 environmental management system and OHSAS18000 occupational safety and health management system issued by the international authoritative agency SGS, and took the lead in realizing the "three certifications" in the pharmaceutical industry. In the 2009 "top 500 most valuable brands in China" list jointly evaluated by world brand laboratory and World Manager weekly, Ma Yinglong ranked 213, with the brand value reaching 4.001 billion yuan. In 2006, Ma Yinglong was awarded "famous protection" by the State Administration for Industry and commerce. In 2009, Ma Yinglong was listed on Shanghai Stock Exchange in 2004 as one of the "top 15 Chinese over-the-counter drug brand enterprises" by China over-the-counter drug association, thus obtaining a channel for continuous financing and a platform for standardized operation. In 2007, the company's stock was selected as the sample stock of China's listed corporate governance index by Shanghai Stock Exchange and China Securities Index company, marking that the level of corporate governance was highly recognized by the public, securities institutions and experts. Inheriting more than 400 years of history and culture, the company has gradually formed a corporate culture system with Ma Yinglong's characteristics. The company adheres to the business tenet of "creating health for customers, creating wealth for shareholders, creating opportunities for employees and creating benefits for the society", advocates the philosophy of "cultivating the heart with sincerity, cultivating the mind with diligence", advocates the business concept of "stable operation and coordinated development", advocates the value concept of "resource added value", and promotes the enterprise spirit of "Longma spirit". Ma Yinglong will take the modernization of traditional Chinese medicine as his duty, keep pace with the times and carry forward the past and open up the future under the guidance of brand management strategy.

本文链接: https://www.waitui.com/brand/92904fecd.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

仁智股份:实控人筹划控制权变更事项,股票停牌

36氪获悉,仁智股份公告,公司收到控股股东、实际控制人陈泽虹通知,其正在筹划公司控制权变更相关事宜,可能导致公司控股股东、实际控制人发生变更。公司股票自2026年5月14日开市起停牌,预计停牌时间不超过2个交易日。本次控制权变更拟转让的股权比例为总股本的19.51%。

54分钟前

日本4月企业破产数达883家,同比增加6.6%

日本东京商工调查公司5月13日公布的日本全国4月破产企业数(负债额1000万日元以上)较上年同期增加6.6%至883家,连续5个月同比增加。人手不足及物价高涨使经营承压,负债总额增加8.8%至1118亿日元。(界面)

54分钟前

美股大型科技股盘前涨跌不一,美光科技涨超4%

36氪获悉,美股大型科技股盘前涨跌不一,截至发稿,美光科技涨超4%,英特尔涨超2%,英伟达涨超1%,特斯拉涨0.17%,Meta跌0.86%,微软跌0.61%,苹果跌0.17%。

54分钟前

山东赫达:澄清实控人减持、质押及美国工厂等不实传闻

36氪获悉,山东赫达公告,公司关注到网络平台有关公司的不实传闻,包括实控人毕于成家族紧急减持、股权质押爆仓、资产注入终止、董事长被调查及美国工厂出问题等。经核实,公司实际控制人毕心德及其一致行动人毕于东、毕文娟合计持股39.75%,自上市以来除2021年、2019-2020年减持外无其他减持,目前无减持计划;其股票质押已于2023年6月全部解除,目前无质押;未披露或实施个人资产注入计划。截至本公告披露日,公司董事长毕于东正常履职,近期不存在接受行政机关或司法机关等公权力机关的调查、谈话或被要求协助调查、被采取留置等强制措施的异常情形。美国工厂项目正常推进,预计2026年投产。公司经营正常,无应披露未披露重大事项。

54分钟前

热门中概股美股盘前多数下跌,阿里巴巴跌超3%

36氪获悉,热门中概股美股盘前多数下跌,截至发稿,阿里巴巴跌超3%,小鹏集团跌超1%,百度跌0.6%,蔚来跌0.49%,哔哩哔哩跌0.37%,理想汽车跌0.27%,京东涨超2%,拼多多涨0.13%。

54分钟前

本页详细列出关于马应龙八宝Mabo's的品牌信息,含品牌所属公司介绍,马应龙八宝Mabo's所处行业的品牌地位及优势。
咨询